exidavnemab vs UB-312

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Parkinson's Disease

Shared mechanism: alpha-synuclein · full Parkinson's Disease pipeline

exidavnemab

Developed by BioArctic AB and partners

Phase 2 in Parkinson's Diseasemonoclonal antibody
Weak signal

NCT06671938 · Phase 2 · completed

This is a randomized, double-blind, placebo-controlled trial, but it enrolled only 38 participants split across dose cohorts, its primary endpoint measures adverse-event incidence rather than efficacy, and results have not yet been posted, so no conclusion about benefit can be drawn. Its registered primary outcome on ClinicalTrials.gov is "Number of participants with adverse events (AEs) and serious adverse events (SAEs).". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

No aligned efficacy figure on record for this race.

UB-312

Developed by Vaxxinity

Phase 1 in Parkinson's Diseasevaccine
Partial signal

NCT04075318 · Phase 1 · completed

A randomized, quadruple-blind, placebo-controlled phase 1 study of the UB-312 vaccine in 70 participants. The design is sound but small, and its primary measures were safety and immunogenicity: anti-alpha-synuclein antibody responses were reported in blood while cerebrospinal-fluid responses were only partial, with no statistical analyses posted, so the primary outcomes read as mixed.

Reported efficacy

Frequency of Adverse Events (44 weeks); Immunogenicity of UB-312 as Determined by Anti-aSyn Antibodies in Blood (44 weeks); Immunogenicity of UB-312 as Determined by Anti-aSyn Antibodies in CSF (44 weeks): Frequency of Adverse Events (44 weeks): Part A: UB-312 40 mcg 22 TEAEs | Part A: UB-312 100 mcg 31 TEAEs | Part A: UB-312 40/300 mcg 25 TEAEs | Part A: UB-312 300 mcg 31 TEAEs | Part A: UB-312 40/1000 mcg 24 TEAEs | Part A: UB-312 1000 mcg 17 TEAEs | Part A: UB-312 2000 mcg 18 TEAEs | Part A: Placebo 25 TEAEs | Part B: UB-312 300/100 mcg 59 TEAEs | Part B: UB-312 300 mcg 42 TEAEs | Part B: Placebo 20 TEAEs (mixed)

Result source: NCT04075318

Results for Parkinson's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointexidavnemabUB-312
OFF time, change—Not reported—Not reported
ON time without troublesome dyskinesia, change—Not reported—Not reported
UPDRS Part III, change—Not reported—Not reported
MDS-UPDRS Part II, change—Not reported—Not reported

OFF time, change

exidavnemab
—Not reported
UB-312
—Not reported

ON time without troublesome dyskinesia, change

exidavnemab
—Not reported
UB-312
—Not reported

UPDRS Part III, change

exidavnemab
—Not reported
UB-312
—Not reported

MDS-UPDRS Part II, change

exidavnemab
—Not reported
UB-312
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

exidavnemab: no structured comparison results are available for Parkinson's Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. exidavnemab: 0 of 4 rows · UB-312: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricUB-312
Dropout rate
100%2000 mcga
NCT04075318 · Phase 1 · monotherapy
show 8 more results
100%1000 mcg
NCT04075318 · Phase 1 · monotherapy
100%40/1000 mcg
NCT04075318 · Phase 1 · monotherapy
0%300 mcg
NCT04075318 · Phase 1 · monotherapy
16.7%40/300 mcg
NCT04075318 · Phase 1 · monotherapy
0%300 mcg
NCT04075318 · Phase 1 · monotherapy
14.3%300/100 mcg
NCT04075318 · Phase 1 · monotherapy
0%100 mcg
NCT04075318 · Phase 1 · monotherapy
0%40 mcg
NCT04075318 · Phase 1 · monotherapy
Discontinued due to AEs
—2000 mcga
NCT04075318 · Phase 1 · monotherapy
show 8 more results
—1000 mcg
NCT04075318 · Phase 1 · monotherapy
—40/1000 mcg
NCT04075318 · Phase 1 · monotherapy
—300 mcg
NCT04075318 · Phase 1 · monotherapy
—40/300 mcg
NCT04075318 · Phase 1 · monotherapy
—300 mcg
NCT04075318 · Phase 1 · monotherapy
—300/100 mcg
NCT04075318 · Phase 1 · monotherapy
—100 mcg
NCT04075318 · Phase 1 · monotherapy
—40 mcg
NCT04075318 · Phase 1 · monotherapy
Serious AEs
0%2000 mcga
NCT04075318 · Phase 1 · monotherapy
show 8 more results
0%1000 mcg
NCT04075318 · Phase 1 · monotherapy
0%40/1000 mcg
NCT04075318 · Phase 1 · monotherapy
0%300 mcg
NCT04075318 · Phase 1 · monotherapy
0%40/300 mcg
NCT04075318 · Phase 1 · monotherapy
0%300 mcg
NCT04075318 · Phase 1 · monotherapy
42.9%300/100 mcg
NCT04075318 · Phase 1 · monotherapy
0%100 mcg
NCT04075318 · Phase 1 · monotherapy
0%40 mcg
NCT04075318 · Phase 1 · monotherapy
Most frequent reported AEs
2000 mcga
general disorders and administration site conditions 83.3% (placebo 62.5%)
nervous system disorders 66.7% (placebo 62.5%)
infections and infestations 50% (placebo 62.5%)
NCT04075318 · Phase 1 · monotherapy
show 8 more results
1000 mcg
general disorders and administration site conditions 100% (placebo 62.5%)
infections and infestations 33.3% (placebo 62.5%)
nervous system disorders 33.3% (placebo 62.5%)
NCT04075318 · Phase 1 · monotherapy
40/1000 mcg
general disorders and administration site conditions 66.7% (placebo 62.5%)
infections and infestations 50% (placebo 62.5%)
nervous system disorders 50% (placebo 62.5%)
NCT04075318 · Phase 1 · monotherapy
300 mcg
general disorders and administration site conditions 100% (placebo 62.5%)
muscoloskeletal and connective tissue disorders 66.7% (placebo 25%)
nervous system disorders 50% (placebo 62.5%)
NCT04075318 · Phase 1 · monotherapy
40/300 mcg
general disorders and administration site conditions 66.7% (placebo 62.5%)
infections and infestations 50% (placebo 62.5%)
nervous system disorders 50% (placebo 62.5%)
NCT04075318 · Phase 1 · monotherapy
300 mcg
nervous system disorders 100% (placebo 62.5%)
infections and infestations 71.4% (placebo 62.5%)
vascular disorders 42.9% (placebo 0%)
NCT04075318 · Phase 1 · monotherapy
300/100 mcg
injury, poisoning and procedural complications 85.7% (placebo 0%)
nervous system disorders 85.7% (placebo 62.5%)
general disorders and administration site conditions 57.1% (placebo 62.5%)
NCT04075318 · Phase 1 · monotherapy
100 mcg
general disorders and administration site conditions 66.7% (placebo 62.5%)
infections and infestations 66.7% (placebo 62.5%)
nervous system disorders 50% (placebo 62.5%)
NCT04075318 · Phase 1 · monotherapy
40 mcg
general disorders and administration site conditions 83.3% (placebo 62.5%)
nervous system disorders 66.7% (placebo 62.5%)
muscoloskeletal and connective tissue disorders 33.3% (placebo 25%)
NCT04075318 · Phase 1 · monotherapy

Notes

  1. aPopulation comparability has not been reviewed for these studies.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: exidavnemab's landscape · UB-312's landscape